Intas Pharmaceuticals is facing renewed regulatory pressure in the US after the Food and Drug Administration (FDA) issued a warning letter to its Dehradun facility, flagging serious lapses in quality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results